⌕
Kiniksa Pharmaceuticals International · KNSA · Nasdaq
Tenet 55 · Mixed
Compare
$95.11+0.93%At closeTenet 55 · Mixed
$95.11+0.88 (+0.93%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Kiniksa Pharmaceuticals International (KNSA) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is KNSA's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Defense WorldNov 17, 2026 · 08:04 ET
Kiniksa Pharmaceuticals International, plc $KNSA Stock: Aberdeen Group plc Reduces Stake

Aberdeen Group plc decreased its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) by 13.9% during the third quarter, according to the company in its most recent disclosure with the Securiti…

KNSA +0.9% todayRead at source ↗
● Defense WorldNov 15, 2026 · 11:34 ET
74,458 Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC trimmed its position in Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) by 18.7% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 323,80…

KNSA +0.9% todayRead at source ↗
● GlobeNewsWireNov 11, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London

LONDON, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in Lon…

KNSA +0.9% todayRead at source ↗
● Defense WorldNov 7, 2026 · 05:17 ET
AlphaCentric Advisors LLC Acquires New Position in Kiniksa Pharmaceuticals International, plc $KNSA

AlphaCentric Advisors LLC bought a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) during a recent quarter, according to its most recent 13F filing with the SEC. The firm bought 7,987 …

KNSA +0.9% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 10:51 ET
Here's Why Kiniksa Pharmaceuticals International, plc (KNSA) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.…

KNSA +0.9% todayRead at source ↗
● The Motley FoolOct 27, 2026 · 13:51 ET
Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors

Kiniksa raised 2026 revenue guidance to over $1.045 billion. ARCALYST penetration among multiple recurrence patients reached 23%.…

KNSA +0.9% todayRead at source ↗
● MarketBeatOct 27, 2026 · 12:06 ET
What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call

Kiniksa Pharmaceuticals International NASDAQ: KNSA raised its full-year 2026 revenue guidance after reporting third-quarter ARCALYST revenue growth of 58% year over year, as the company continued to expand use of the dru…

KNSA +0.9% todayRead at source ↗
● Seeking AlphaOct 27, 2026 · 11:30 ET
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript…

KNSA +0.9% todayRead at source ↗
● Zacks Investment ResearchOct 27, 2026 · 09:50 ET
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.23 per share a year ago.…

KNSA +0.9% todayRead at source ↗
● GlobeNewsWireOct 27, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion – – KPL-387 pivotal Pha…

KNSA +0.9% todayRead at source ↗
● GlobeNewsWireOct 22, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026

LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern T…

KNSA +0.9% todayRead at source ↗
● Defense WorldOct 21, 2026 · 04:01 ET
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High – Still a Buy?

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report)'s share price reached a new 52-week high during trading on Wednesday. The company traded as high as $83.78 and last traded at $83.17, with a vol…

KNSA +0.9% todayRead at source ↗
● Defense WorldOct 16, 2026 · 03:47 ET
10,232 Shares of Kiniksa Pharmaceuticals International, plc $KNSA Acquired by B. Riley Wealth Advisors Inc.

B. Riley Wealth Advisors Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) during the third quarter, according to the company in its most recent Form 13F filing with the …

KNSA +0.9% todayRead at source ↗
● Defense WorldOct 16, 2026 · 02:59 ET
Head-To-Head Survey: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Mirum Pharmaceuticals (NASDAQ:MIRM)

Mirum Pharmaceuticals (NASDAQ: MIRM - Get Free Report) and Kiniksa Pharmaceuticals International (NASDAQ: KNSA - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will compare th…

KNSA +0.9% todayRead at source ↗
● Defense WorldSep 25, 2026 · 04:15 ET
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock Has Consensus Price Target of $87.38 According to Brokerages

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the company, MarketBeat reports. …

KNSA +0.9% todayRead at source ↗
● Zacks Investment ResearchSep 17, 2026 · 13:17 ET
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why

KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.…

KNSA +0.9% todayRead at source ↗
● GlobeNewsWireSep 4, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conferenc…

KNSA +0.9% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just KNSA · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.